<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01152450</url>
  </required_header>
  <id_info>
    <org_study_id>205.420</org_study_id>
    <secondary_id>2009-018006-21</secondary_id>
    <nct_id>NCT01152450</nct_id>
  </id_info>
  <brief_title>A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma</brief_title>
  <official_title>A Phase II, Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Administered Once Daily (in the Evening) and Tiotropium 2.5 µg Administered Twice Daily Delivered by the Respimat® Inhaler for Four Weeks Versus Placebo in Patients With Moderate Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Rationale for the current trial is to demonstrate 24 hour bronchodilator efficacy and safety
      of tiotropium 5 µg administered once daily (in the evening) which is regarded beneficial for
      the compliance and convenience of the patient in comparison to placebo. Further the rationale
      is to evaluate efficacy and safety of tiotropium 2.5 µg administered twice daily delivered by
      the Respimat® inhaler in comparison to placebo and tiotropium 5 µg administered once daily
      (in the evening) delivered by the Respimat® inhaler in patients with moderate persistent
      asthma.

      Rationale for the pharmacokinetic subinvestigation is to evaluate the 24 hours exposure to
      tiotropium in patients with moderate persistent asthma when administered 5 µg tiotropium once
      daily (in the evening) or 2.5 µg tiotropium twice daily.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve 0-24 Hours (AUC0-24h) Response</measure>
    <time_frame>10 minutes (min) prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 hours (h) , 3 h, 4 h , 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4</time_frame>
    <description>Mixed Model Repeated Measure (MMRM) results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measurements performed in relation to evening dosing. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Morning Peak Expiratory Flow (PEF a.m.) Response During the Last Week on Treatment</measure>
    <time_frame>Baseline and during week 4 of each treatment period</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured by patients at home using the AM2+ device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Evening Peak Expiratory Flow (PEF p.m.) Response During the Last Week on Treatment</measure>
    <time_frame>Baseline and during week 4 of each treatment period</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured by patients at home using the AM2+ device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Area Under the Curve 0-12 Hours (AUC0-12h) Response</measure>
    <time_frame>10 min prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 h, 3 h, 4 h and 11 h 50 min related to evening dose at week 4</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC0-12h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Area Under the Curve 12-24 Hours (AUC12-24h) Response</measure>
    <time_frame>10 min prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC12-24h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 Within 24 Hours Post-dose Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the evening trial-drug inhalation at the end of each 4 week period of randomised treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Trough FEV1 is defined as FEV1 value (performed at 10 minutes prior to the evening trial-drug inhalation) at the end of each 4 week period of randomised treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Vital Capacity (FVC) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Trough FVC is defined as FVC value (performed at 10 minutes prior to the evening trial-drug inhalation) at the end of each 4 week period of randomised treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under the Curve 0-12 Hours (AUC0-12h) Response</measure>
    <time_frame>10 min prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 h, 3 h, 4 h and 11 h 50 min related to evening dose at week 4</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following each dosing determined at the end of each 4 week treatment period. AUC0-12h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under the Curve 12-24 Hours (AUC12-24h) Response</measure>
    <time_frame>10 min prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following each dosing determined at the end of each 4 week treatment period. AUC12-24h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FVC Within 24 Hours Post-dose Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following each dosing determined at the end of each 4 week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual FEV1 Over Time (at Each Timepoint at Visits) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual FVC Over Time (at Each Timepoint at Visits) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Peak Expiratory Flow (PEF) Over Time (at Each Timepoint at Visits) Response</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under the Curve 0-24 Hours (AUC0-24h) Response</measure>
    <time_frame>10 min prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 h, 3 h, 4 h , 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF Area Under the Curve 0-24 Hours (AUC0-24h) Response</measure>
    <time_frame>10 min prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 h, 3 h, 4 h , 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres/min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF Variability Response (Last Week on Treatment)</measure>
    <time_frame>Baseline and during week 4</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. PEF variability is the absolute difference between morning and evening PEF value divided by the mean of these two values, expressed as a percent (weekly means obtained during the last week of each period of randomised treatment will be compared).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Rescue Medication During the Whole Day (Last Week on Treatment, Response Values)</measure>
    <time_frame>Baseline and during week 4</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Rescue Medication During Daytime (Last Week on Treatment, Response Values)</measure>
    <time_frame>Baseline and during week 4</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Rescue Medication During Nighttime (Last Week on Treatment, Response Values)</measure>
    <time_frame>Baseline and during week 4</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Night Awakenings During the Last Week on Treatment (Score, Response Values)</measure>
    <time_frame>Baseline and during week 4</time_frame>
    <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Assessed by the patient's electronic diary (eDiary incorporated in the AM2+ device), obtained during the last week of each period of randomised treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Tiotropium daily dose q.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two actuations delivered via Respimat® inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium half daily dose b.i.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>two actuations delivered via Respimat® inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N/A (two actuations of placebo) delivered via Respimat® inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium 2.5 µg b.i.d</intervention_name>
    <description>2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler</description>
    <arm_group_label>Tiotropium half daily dose b.i.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>N/A (two actuations of placebo) delivered via Respimat® inhaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium 5 µg q.d.</intervention_name>
    <description>5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler</description>
    <arm_group_label>Tiotropium daily dose q.d.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. All patients must sign and date an Informed Consent Form consistent with International
             Conference on Harmonisation of Technical Requirements for Registration of
             Pharmaceuticals for Human Use Good Clinical Practice ( ICH-GCP) guidelines and local
             legislation prior to participation in the trial (i.e. prior to any trial procedures,
             including any pre-trial washout of medications and medication restrictions for
             pulmonary function test at Visit 1).

          2. Male or female patients aged at least 18 years but not more than 75 years.

          3. All patients must have at least a 3 months history of asthma at the time of enrolment
             into the trial. The diagnosis of asthma has to be confirmed at Visit 1 with a
             bronchodilator reversibility resulting in a Forced Expiratory Volume in 1 Second
             (FEV1) increase of equal above 12% and equal above 200mL.

          4. The initial diagnosis of asthma must have been made before the patient's age of 40.

          5. All patients must have a diagnosis of moderate persistent asthma and must be
             symptomatic despite their current maintenance treatment with medium doses of inhaled
             corticosteroids.

          6. All patients must have been on maintenance treatment with a medium, stable dose of
             inhaled corticosteroids (alone or in a fixed combination with a Long Acting
             Betaadrenergic (LABA) or Short Acting Betaadrenergic (SABA)) for at least 4 weeks
             prior to Visit 1.

          7. All patients must be symptomatic at Visit 1 (screening) and Visit 2 as defined by an
             Asthma Control Questionnaire (ACQ) Score

          8. All patients must have a pre-bronchodilator FEV1 above equal 60% predicted and below
             equal 90% of predicted normal at Visit 1. Predicted normal values will be calculated
             according to the European Coal and Steel Community Guidelines (ECSC).

          9. All patients must have an increase in FEV1 of equal above 12% and equal above 200 mL
             15 minutes after 400 µg salbutamol at Visit 1.

         10. Variation of absolute FEV1 values of Visit 1 (pre-bronchodilator) as compared to Visit
             2 (pre-dose) must be within ± 30% .

         11. Patients must be never-smokers or ex-smokers who stopped smoking at least one year
             prior to enrolment and who have a smoking history of less than 10 pack years.

         12. Patients must be able to use the Respimat® inhaler correctly.

         13. Patients must be able to perform all trial related procedures including technically
             acceptable pulmonary function tests and use of the e-Diary/peak flow meter.

         14. Patients taking a chronic pulmonary medication allowed by the study protocol must be
             willing to continue this therapy for the entire duration of the study (exception:
             times of acute disease deterioration).

        Exclusion criteria:

          1. Patients with a significant disease other than asthma.A significant disease is defined
             as a disease which, in the opinion of the investigator, may (i) put the patient at
             risk because of participation in the trial, or (ii) influence the results of the
             trial, or (iii) cause concern regarding the patient's ability to participate in the
             trial.

          2. Patients with a clinically relevant abnormal screening hematology or blood chemistry
             if the abnormality defines a significant disease as defined in exclusion criterion no.
             1.

          3. Patients with a recent history (i.e. six months or less) of myocardial infarction.

          4. Patients who have been hospitalised for cardiac failure during the past year.

          5. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac
             arrhythmia requiring intervention or a change in drug therapy within the past year.

          6. Patients with lung diseases other than asthma (e.g. Chronic Obstructive Lung Disease
             (COPD)).

          7. Patients with known active tuberculosis.

          8. Patients with malignancy for which the patient has undergone resection, radiation
             therapy or chemotherapy within the last five years. Patients with treated basal cell
             carcinoma are allowed.

          9. Patients who have undergone thoracotomy with pulmonary resection.

         10. Patients with significant alcohol or drug abuse within the past two years.

         11. Patients who are currently in a pulmonary rehabilitation program or have completed a
             pulmonary rehabilitation program in the 6 weeks prior to V 1.

         12. Patients with known hypersensitivity to anticholinergic drugs, Benzalconiumchloride
             (BAC), Ethylenediaminetetraacetate (EDTA) or any other components of the study
             medication delivery systems.

         13. Pregnant or nursing women.

         14. Women of childbearing potential not using a highly effective method of birth control.

         15. Patients who have been treated with beta-blocker medication within four weeks prior to
             Visit 1 or during the screening period. Topical cardio-selective beta-blocker eye
             medications for non-arrow angle glaucoma are allowed.

         16. Patients who have been treated with the long-acting anticholinergic tiotropium
             (Spiriva®) within four weeks prior to Visit 1 or during the screening period.

         17. Patients who have been treated with oral beta-adrenergics within four weeks prior to
             Visit 1 or during the screening period.

         18. Patients who have been treated with oral corticosteroids within four weeks prior to
             Visit 1 or during the screening period.

         19. Patients who have been treated with anti-IgE antibodies, e.g. omalizumab (Xolair®),
             within 6 months prior to Visit 1 or during the screening period.20. Patients who have
             been treated with cromolyn sodium or nedocromil sodium within two weeks prior to Visit
             1 or during the screening period.

        21. Patients who have been treated with methylxanthines within two weeks prior to Visit 1
        or during the screening period.

        22. Patients who have taken an investigational drug within four weeks prior to Visit 1.

        23. Patients who have been treated with other non-approved and according to international
        guidelines not recommended &quot;experimental&quot; drugs for routine asthma therapy (e.g. TNFalpha
        blockers, methotrexate, cyclosporin) within four weeks prior to Visit 1 or during the
        screening period.

        24. Patients with any asthma exacerbation or any respiratory tract infection in the four
        weeks prior to Visit 1 or during the screening period. Visit 1 and/or Visit 2 should be
        postponed in case of an asthma exacerbation or respiratory tract infection.

        25. Patients who have previously been randomised in this trial or are currently
        participating in another trial.

        26.Patients who have been treated with depot corticosteroids within six months prior to
        Visit 1 or during the screening period.

        27.Patients who have been treated with leukotriene modifiers within two weeks prior to
        Visit 1 or during the screening period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.420.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.420.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schlüsslberg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.420.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thalheim bei Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.420.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.420.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.420.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyjov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.420.37201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kohtla-Järve</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.420.37202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.420.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.420.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.420.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.420.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.420.37102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.420.37101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.420.37103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Latvia</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2010</study_first_posted>
  <results_first_submitted>August 17, 2012</results_first_submitted>
  <results_first_submitted_qc>September 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 30, 2012</results_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 94 patients entered the study and was treated whilst 89 patients completed the trial.</recruitment_details>
      <pre_assignment_details>Randomised, double-blind, placebo controlled, cross-over design without washout phase between the three periods. Patients were randomized equally to one of the six sequences (ABC, ACB, BAC, BCA, CAB, CBA).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tio R2.5 Twice Daily (Bid) /Tio R5 Once Daily (qd) /Placebo</title>
          <description>Patients treated with Tiotropium 2.5 mcg in period 1 (morning and evening), with a matching placebo in the morning and Tiotropium 5 mcg in the evening in period 2 and with a matching Placebo in period 3 (morning and evening). All products were delivered by the Respimat inhaler, on top on maintenance therapy with inhaled corticosteroid (iCS). No washouts (off-treatment periods) between treatments. Duration of each treatment period was 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Tio R2.5 Bid/Placebo/Tio R5 qd</title>
          <description>Patients treated with Tiotropium 2.5 mcg in period 1 (morning and evening), with a matching Placebo in period 2 (morning and evening) and with a matching placebo in the morning and Tiotropium 5 mcg in the evening in period 3. All products were delivered by the Respimat inhaler, on top on maintenance therapy with iCS. No washouts (off-treatment periods) between treatments. Duration of each treatment period was 4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Tio R5 qd/Tio R2.5 Bid/Placebo</title>
          <description>Patients treated with a matching placebo in the morning and Tiotropium 5 mcg in the evening in period 1, with Tiotropium 2.5 mcg in period 2 (morning and evening) and with matching Placebo in period 3 (morning and evening) . All products were delivered by the Respimat inhaler, on top on maintenance therapy with iCS. No washouts (off-treatment periods) between treatments. Duration of each treatment period was 4 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Tio R5 qd/Placebo/Tio R2.5 Bid</title>
          <description>Patients treated with a matching placebo in the morning and Tiotropium 5 mcg in the evening in period 1, with matching Placebo in period 2 (morning and evening) and with Tiotropium 2.5 mcg in period 3 (morning and evening) . All products were delivered by the Respimat inhaler, on top on maintenance therapy with iCS. No washouts (off-treatment periods) between treatments. Duration of each treatment period was 4 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Placebo/Tio R2.5 Bid/Tio R5 qd</title>
          <description>Patients treated with matching Placebo in period 1 (morning and evening), with Tiotropium 2.5 mcg in period 2 (morning and evening) and with a matching placebo in the morning and Tiotropium 5 mcg in the evening in period 3. All products were delivered by the Respimat inhaler, on top on maintenance therapy with iCS. No washouts (off-treatment periods) between treatments. Duration of each treatment period was 4 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Placebo/Tio R5 qd/Tio R2.5 Bid</title>
          <description>Patients treated with a matching Placebo in period 1 (morning and evening), with a matching placebo in the morning and Tiotropium 5 mcg in the evening in period 2 and with Tiotropium 2.5 mcg in period 3 (morning and evening) . All products were delivered by the Respimat inhaler, on top on maintenance therapy with iCS. No washouts (off-treatment periods) between treatments. Duration of each treatment period was 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3 (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Baseline Total</title>
          <description>Total number of patients randomised and treated in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.3" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve 0-24 Hours (AUC0-24h) Response</title>
        <description>Mixed Model Repeated Measure (MMRM) results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measurements performed in relation to evening dosing. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres.</description>
        <time_frame>10 minutes (min) prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 hours (h) , 3 h, 4 h , 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4</time_frame>
        <population>Full Analysis Set (FAS) defined as all treated patients who had baseline data and at least 1 on-treatment efficacy measurement after 4 weeks on treatment within a period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve 0-24 Hours (AUC0-24h) Response</title>
          <description>Mixed Model Repeated Measure (MMRM) results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measurements performed in relation to evening dosing. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres.</description>
          <population>Full Analysis Set (FAS) defined as all treated patients who had baseline data and at least 1 on-treatment efficacy measurement after 4 weeks on treatment within a period.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.091" spread="0.043"/>
                    <measurement group_id="O2" value="0.241" spread="0.044"/>
                    <measurement group_id="O3" value="0.250" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.149</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.102</ci_lower_limit>
            <ci_upper_limit>0.196</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM, adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.158</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.111</ci_lower_limit>
            <ci_upper_limit>0.205</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.009</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.038</ci_lower_limit>
            <ci_upper_limit>0.056</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Morning Peak Expiratory Flow (PEF a.m.) Response During the Last Week on Treatment</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured by patients at home using the AM2+ device.</description>
        <time_frame>Baseline and during week 4 of each treatment period</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Morning Peak Expiratory Flow (PEF a.m.) Response During the Last Week on Treatment</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured by patients at home using the AM2+ device.</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.953" spread="5.864"/>
                    <measurement group_id="O2" value="23.281" spread="5.907"/>
                    <measurement group_id="O3" value="24.310" spread="5.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>21.328</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.190</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>11.084</ci_lower_limit>
            <ci_upper_limit>31.573</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22.357</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.225</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>12.044</ci_lower_limit>
            <ci_upper_limit>32.670</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.029</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.242</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.318</ci_lower_limit>
            <ci_upper_limit>11.376</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Evening Peak Expiratory Flow (PEF p.m.) Response During the Last Week on Treatment</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured by patients at home using the AM2+ device.</description>
        <time_frame>Baseline and during week 4 of each treatment period</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Evening Peak Expiratory Flow (PEF p.m.) Response During the Last Week on Treatment</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured by patients at home using the AM2+ device.</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.560" spread="5.891"/>
                    <measurement group_id="O2" value="28.360" spread="5.932"/>
                    <measurement group_id="O3" value="27.096" spread="5.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>29.920</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>20.001</ci_lower_limit>
            <ci_upper_limit>39.839</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>28.657</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.042</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>18.707</ci_lower_limit>
            <ci_upper_limit>38.606</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.264</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.243</ci_lower_limit>
            <ci_upper_limit>8.716</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Area Under the Curve 0-12 Hours (AUC0-12h) Response</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC0-12h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.</description>
        <time_frame>10 min prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 h, 3 h, 4 h and 11 h 50 min related to evening dose at week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Area Under the Curve 0-12 Hours (AUC0-12h) Response</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC0-12h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.</description>
          <population>FAS</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.048" spread="0.044"/>
                    <measurement group_id="O2" value="0.217" spread="0.044"/>
                    <measurement group_id="O3" value="0.233" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.169</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.120</ci_lower_limit>
            <ci_upper_limit>0.218</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.185</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.136</ci_lower_limit>
            <ci_upper_limit>0.234</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.016</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.033</ci_lower_limit>
            <ci_upper_limit>0.065</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Area Under the Curve 12-24 Hours (AUC12-24h) Response</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC12-24h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.</description>
        <time_frame>10 min prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Area Under the Curve 12-24 Hours (AUC12-24h) Response</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the respective dosing determined at the end of each 4 week period of randomised treatment. AUC12-24h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.</description>
          <population>FAS</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.135" spread="0.044"/>
                    <measurement group_id="O2" value="0.264" spread="0.045"/>
                    <measurement group_id="O3" value="0.266" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.129</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.181</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.131</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.079</ci_lower_limit>
            <ci_upper_limit>0.183</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.002</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.050</ci_lower_limit>
            <ci_upper_limit>0.054</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 Within 24 Hours Post-dose Response</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the evening trial-drug inhalation at the end of each 4 week period of randomised treatment.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 Within 24 Hours Post-dose Response</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following the evening trial-drug inhalation at the end of each 4 week period of randomised treatment.</description>
          <population>FAS</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.337" spread="0.045"/>
                    <measurement group_id="O2" value="0.469" spread="0.045"/>
                    <measurement group_id="O3" value="0.468" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.084</ci_lower_limit>
            <ci_upper_limit>0.179</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.131</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.084</ci_lower_limit>
            <ci_upper_limit>0.179</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.000</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.048</ci_lower_limit>
            <ci_upper_limit>0.047</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Trough FEV1 is defined as FEV1 value (performed at 10 minutes prior to the evening trial-drug inhalation) at the end of each 4 week period of randomised treatment.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Trough FEV1 is defined as FEV1 value (performed at 10 minutes prior to the evening trial-drug inhalation) at the end of each 4 week period of randomised treatment.</description>
          <population>FAS</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.143" spread="0.044"/>
                    <measurement group_id="O2" value="0.254" spread="0.044"/>
                    <measurement group_id="O3" value="0.275" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.053</ci_lower_limit>
            <ci_upper_limit>0.170</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.133</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.029</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.191</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.021</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.037</ci_lower_limit>
            <ci_upper_limit>0.080</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Vital Capacity (FVC) Response</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Trough FVC is defined as FVC value (performed at 10 minutes prior to the evening trial-drug inhalation) at the end of each 4 week period of randomised treatment.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Vital Capacity (FVC) Response</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Trough FVC is defined as FVC value (performed at 10 minutes prior to the evening trial-drug inhalation) at the end of each 4 week period of randomised treatment.</description>
          <population>FAS</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.112" spread="0.046"/>
                    <measurement group_id="O2" value="0.179" spread="0.046"/>
                    <measurement group_id="O3" value="0.168" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0515</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.000</ci_lower_limit>
            <ci_upper_limit>0.136</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1058</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.124</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.080</ci_lower_limit>
            <ci_upper_limit>0.057</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under the Curve 0-12 Hours (AUC0-12h) Response</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following each dosing determined at the end of each 4 week treatment period. AUC0-12h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.</description>
        <time_frame>10 min prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 h, 3 h, 4 h and 11 h 50 min related to evening dose at week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under the Curve 0-12 Hours (AUC0-12h) Response</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following each dosing determined at the end of each 4 week treatment period. AUC0-12h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.</description>
          <population>FAS</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.026" spread="0.046"/>
                    <measurement group_id="O2" value="0.099" spread="0.046"/>
                    <measurement group_id="O3" value="0.074" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.125</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.073</ci_lower_limit>
            <ci_upper_limit>0.177</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.100</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.048</ci_lower_limit>
            <ci_upper_limit>0.152</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.025</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.077</ci_lower_limit>
            <ci_upper_limit>0.027</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under the Curve 12-24 Hours (AUC12-24h) Response</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following each dosing determined at the end of each 4 week treatment period. AUC12-24h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.</description>
        <time_frame>10 min prior to first dose (baseline) and 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under the Curve 12-24 Hours (AUC12-24h) Response</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following each dosing determined at the end of each 4 week treatment period. AUC12-24h calculated using the trapezoidal rule divided by the observation time (12 hours) to report in litres.</description>
          <population>FAS</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.032" spread="0.045"/>
                    <measurement group_id="O2" value="0.108" spread="0.045"/>
                    <measurement group_id="O3" value="0.100" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0051</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.023</ci_lower_limit>
            <ci_upper_limit>0.129</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0123</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.015</ci_lower_limit>
            <ci_upper_limit>0.120</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.008</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.061</ci_lower_limit>
            <ci_upper_limit>0.045</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC Within 24 Hours Post-dose Response</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following each dosing determined at the end of each 4 week treatment period.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC Within 24 Hours Post-dose Response</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Measured following each dosing determined at the end of each 4 week treatment period.</description>
          <population>FAS</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.302" spread="0.045"/>
                    <measurement group_id="O2" value="0.380" spread="0.045"/>
                    <measurement group_id="O3" value="0.350" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0042</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.025</ci_lower_limit>
            <ci_upper_limit>0.130</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0747</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>0.100</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.029</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.082</ci_lower_limit>
            <ci_upper_limit>0.023</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual FEV1 Over Time (at Each Timepoint at Visits) Response</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>Individual FEV1 Over Time (at Each Timepoint at Visits) Response</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Timepoint -0:10 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.143" spread="0.044"/>
                    <measurement group_id="O2" value="0.254" spread="0.044"/>
                    <measurement group_id="O3" value="0.275" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 0:30 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.132" spread="0.044"/>
                    <measurement group_id="O2" value="0.281" spread="0.044"/>
                    <measurement group_id="O3" value="0.304" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 1:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.123" spread="0.044"/>
                    <measurement group_id="O2" value="0.274" spread="0.044"/>
                    <measurement group_id="O3" value="0.289" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 2:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.103" spread="0.044"/>
                    <measurement group_id="O2" value="0.270" spread="0.044"/>
                    <measurement group_id="O3" value="0.297" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 3:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.082" spread="0.044"/>
                    <measurement group_id="O2" value="0.264" spread="0.044"/>
                    <measurement group_id="O3" value="0.268" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 4:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.062" spread="0.045"/>
                    <measurement group_id="O2" value="0.248" spread="0.045"/>
                    <measurement group_id="O3" value="0.263" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 11:50 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.021" spread="0.049"/>
                    <measurement group_id="O2" value="0.134" spread="0.049"/>
                    <measurement group_id="O3" value="0.150" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 12:30 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.075" spread="0.047"/>
                    <measurement group_id="O2" value="0.198" spread="0.047"/>
                    <measurement group_id="O3" value="0.217" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 13:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.101" spread="0.047"/>
                    <measurement group_id="O2" value="0.250" spread="0.047"/>
                    <measurement group_id="O3" value="0.237" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 14:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.138" spread="0.045"/>
                    <measurement group_id="O2" value="0.288" spread="0.045"/>
                    <measurement group_id="O3" value="0.282" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 15:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.163" spread="0.046"/>
                    <measurement group_id="O2" value="0.299" spread="0.046"/>
                    <measurement group_id="O3" value="0.308" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 16:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.161" spread="0.046"/>
                    <measurement group_id="O2" value="0.306" spread="0.046"/>
                    <measurement group_id="O3" value="0.313" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 18:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.177" spread="0.047"/>
                    <measurement group_id="O2" value="0.300" spread="0.047"/>
                    <measurement group_id="O3" value="0.308" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 20:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.127" spread="0.045"/>
                    <measurement group_id="O2" value="0.256" spread="0.046"/>
                    <measurement group_id="O3" value="0.245" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 22:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.117" spread="0.047"/>
                    <measurement group_id="O2" value="0.221" spread="0.047"/>
                    <measurement group_id="O3" value="0.244" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 23:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.124" spread="0.045"/>
                    <measurement group_id="O2" value="0.243" spread="0.045"/>
                    <measurement group_id="O3" value="0.223" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 23:50 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.125" spread="0.047"/>
                    <measurement group_id="O2" value="0.232" spread="0.047"/>
                    <measurement group_id="O3" value="0.224" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual FVC Over Time (at Each Timepoint at Visits) Response</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>Individual FVC Over Time (at Each Timepoint at Visits) Response</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Timepoint -0:10 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.112" spread="0.046"/>
                    <measurement group_id="O2" value="0.179" spread="0.046"/>
                    <measurement group_id="O3" value="0.168" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 0:30 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.053" spread="0.047"/>
                    <measurement group_id="O2" value="0.158" spread="0.048"/>
                    <measurement group_id="O3" value="0.130" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 1:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.055" spread="0.047"/>
                    <measurement group_id="O2" value="0.152" spread="0.047"/>
                    <measurement group_id="O3" value="0.124" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 2:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" spread="0.047"/>
                    <measurement group_id="O2" value="0.131" spread="0.047"/>
                    <measurement group_id="O3" value="0.093" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 3:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.003" spread="0.047"/>
                    <measurement group_id="O2" value="0.100" spread="0.047"/>
                    <measurement group_id="O3" value="0.057" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 4:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.040" spread="0.049"/>
                    <measurement group_id="O2" value="0.096" spread="0.049"/>
                    <measurement group_id="O3" value="0.065" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 11:50 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.064" spread="0.049"/>
                    <measurement group_id="O2" value="0.070" spread="0.049"/>
                    <measurement group_id="O3" value="0.060" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 12:30 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.046"/>
                    <measurement group_id="O2" value="0.133" spread="0.046"/>
                    <measurement group_id="O3" value="0.103" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 13:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" spread="0.047"/>
                    <measurement group_id="O2" value="0.114" spread="0.047"/>
                    <measurement group_id="O3" value="0.102" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 14:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.038" spread="0.047"/>
                    <measurement group_id="O2" value="0.106" spread="0.047"/>
                    <measurement group_id="O3" value="0.120" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 15:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" spread="0.047"/>
                    <measurement group_id="O2" value="0.109" spread="0.047"/>
                    <measurement group_id="O3" value="0.124" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 16:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.050" spread="0.047"/>
                    <measurement group_id="O2" value="0.111" spread="0.047"/>
                    <measurement group_id="O3" value="0.116" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 18:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.062" spread="0.046"/>
                    <measurement group_id="O2" value="0.123" spread="0.046"/>
                    <measurement group_id="O3" value="0.113" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 20:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" spread="0.047"/>
                    <measurement group_id="O2" value="0.125" spread="0.047"/>
                    <measurement group_id="O3" value="0.088" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 22:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.028" spread="0.048"/>
                    <measurement group_id="O2" value="0.077" spread="0.048"/>
                    <measurement group_id="O3" value="0.096" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 23:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" spread="0.048"/>
                    <measurement group_id="O2" value="0.094" spread="0.048"/>
                    <measurement group_id="O3" value="0.062" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 23:50 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.015" spread="0.049"/>
                    <measurement group_id="O2" value="0.078" spread="0.049"/>
                    <measurement group_id="O3" value="0.052" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Peak Expiratory Flow (PEF) Over Time (at Each Timepoint at Visits) Response</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.</description>
        <time_frame>Baseline and 4 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Peak Expiratory Flow (PEF) Over Time (at Each Timepoint at Visits) Response</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline.</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Timepoint -0:10 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.770" spread="7.357"/>
                    <measurement group_id="O2" value="42.428" spread="7.378"/>
                    <measurement group_id="O3" value="57.897" spread="7.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 0:30 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.994" spread="7.275"/>
                    <measurement group_id="O2" value="46.272" spread="7.295"/>
                    <measurement group_id="O3" value="58.436" spread="7.277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 1:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.783" spread="7.027"/>
                    <measurement group_id="O2" value="43.049" spread="7.043"/>
                    <measurement group_id="O3" value="53.138" spread="7.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 2:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.366" spread="7.246"/>
                    <measurement group_id="O2" value="48.328" spread="7.263"/>
                    <measurement group_id="O3" value="55.826" spread="7.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 3:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.769" spread="7.457"/>
                    <measurement group_id="O2" value="48.723" spread="7.474"/>
                    <measurement group_id="O3" value="50.747" spread="7.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 4:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.499" spread="7.242"/>
                    <measurement group_id="O2" value="42.599" spread="7.260"/>
                    <measurement group_id="O3" value="50.077" spread="7.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 11:50 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.219" spread="7.747"/>
                    <measurement group_id="O2" value="20.011" spread="7.765"/>
                    <measurement group_id="O3" value="26.201" spread="7.749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 12:30 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.345" spread="7.314"/>
                    <measurement group_id="O2" value="27.436" spread="7.335"/>
                    <measurement group_id="O3" value="33.887" spread="7.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 13:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.820" spread="7.479"/>
                    <measurement group_id="O2" value="33.810" spread="7.499"/>
                    <measurement group_id="O3" value="34.582" spread="7.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 14:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.879" spread="7.323"/>
                    <measurement group_id="O2" value="44.786" spread="7.348"/>
                    <measurement group_id="O3" value="43.371" spread="7.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 15:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.125" spread="6.992"/>
                    <measurement group_id="O2" value="47.991" spread="7.012"/>
                    <measurement group_id="O3" value="45.699" spread="6.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 16:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.616" spread="7.304"/>
                    <measurement group_id="O2" value="47.697" spread="7.330"/>
                    <measurement group_id="O3" value="46.441" spread="7.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 18:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.084" spread="7.303"/>
                    <measurement group_id="O2" value="47.795" spread="7.326"/>
                    <measurement group_id="O3" value="48.790" spread="7.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 20:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.348" spread="7.213"/>
                    <measurement group_id="O2" value="42.240" spread="7.232"/>
                    <measurement group_id="O3" value="40.888" spread="7.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 22:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.275" spread="7.317"/>
                    <measurement group_id="O2" value="33.567" spread="7.339"/>
                    <measurement group_id="O3" value="41.635" spread="7.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 23:00 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.590" spread="7.360"/>
                    <measurement group_id="O2" value="36.712" spread="7.384"/>
                    <measurement group_id="O3" value="38.384" spread="7.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Timepoint 23:50 (hours:minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.169" spread="7.670"/>
                    <measurement group_id="O2" value="36.837" spread="7.697"/>
                    <measurement group_id="O3" value="37.595" spread="7.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under the Curve 0-24 Hours (AUC0-24h) Response</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres.</description>
        <time_frame>10 min prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 h, 3 h, 4 h , 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under the Curve 0-24 Hours (AUC0-24h) Response</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres.</description>
          <population>FAS</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.044"/>
                    <measurement group_id="O2" value="0.104" spread="0.044"/>
                    <measurement group_id="O3" value="0.087" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.101</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.055</ci_lower_limit>
            <ci_upper_limit>0.147</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.084</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.038</ci_lower_limit>
            <ci_upper_limit>0.130</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.016</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.063</ci_lower_limit>
            <ci_upper_limit>0.030</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF Area Under the Curve 0-24 Hours (AUC0-24h) Response</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres/min.</description>
        <time_frame>10 min prior to first dose (baseline) and -10 min, 30 min, 60 min, 2 h, 3 h, 4 h , 11 h 50 min, 12 h 30 min, 13 h, 14 h, 15 h, 16 h, 18 h, 20 h, 22 h, 23 h, and 23 h 50 min related to evening dose at week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>PEF Area Under the Curve 0-24 Hours (AUC0-24h) Response</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. AUC0-24h calculated using the trapezoidal rule divided by the observation time (24 hours) to report in litres/min.</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.589" spread="6.870"/>
                    <measurement group_id="O2" value="38.831" spread="6.883"/>
                    <measurement group_id="O3" value="42.899" spread="6.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>30.242</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.091</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>22.167</ci_lower_limit>
            <ci_upper_limit>38.317</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>34.310</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.089</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>26.240</ci_lower_limit>
            <ci_upper_limit>42.380</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.094</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.012</ci_lower_limit>
            <ci_upper_limit>12.148</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF Variability Response (Last Week on Treatment)</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. PEF variability is the absolute difference between morning and evening PEF value divided by the mean of these two values, expressed as a percent (weekly means obtained during the last week of each period of randomised treatment will be compared).</description>
        <time_frame>Baseline and during week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>PEF Variability Response (Last Week on Treatment)</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. PEF variability is the absolute difference between morning and evening PEF value divided by the mean of these two values, expressed as a percent (weekly means obtained during the last week of each period of randomised treatment will be compared).</description>
          <population>FAS</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.296" spread="0.711"/>
                    <measurement group_id="O2" value="0.619" spread="0.718"/>
                    <measurement group_id="O3" value="0.685" spread="0.721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6747</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.323</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.769</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.195</ci_lower_limit>
            <ci_upper_limit>1.841</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6159</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.389</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.774</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.138</ci_lower_limit>
            <ci_upper_limit>1.916</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.777</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.468</ci_lower_limit>
            <ci_upper_limit>1.599</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Rescue Medication During the Whole Day (Last Week on Treatment, Response Values)</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared.</description>
        <time_frame>Baseline and during week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Rescue Medication During the Whole Day (Last Week on Treatment, Response Values)</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared.</description>
          <population>FAS</population>
          <units>Puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.841" spread="0.189"/>
                    <measurement group_id="O2" value="-0.917" spread="0.190"/>
                    <measurement group_id="O3" value="-1.016" spread="0.190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5906</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.142</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.358</ci_lower_limit>
            <ci_upper_limit>0.204</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2208</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.143</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.458</ci_lower_limit>
            <ci_upper_limit>0.106</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.143</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.382</ci_lower_limit>
            <ci_upper_limit>0.184</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Rescue Medication During Daytime (Last Week on Treatment, Response Values)</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared.</description>
        <time_frame>Baseline and during week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Rescue Medication During Daytime (Last Week on Treatment, Response Values)</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared.</description>
          <population>FAS</population>
          <units>Puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.562" spread="0.106"/>
                    <measurement group_id="O2" value="-0.564" spread="0.106"/>
                    <measurement group_id="O3" value="-0.624" spread="0.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9797</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.002</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.082</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.163</ci_lower_limit>
            <ci_upper_limit>0.159</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4518</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.062</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.082</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.223</ci_lower_limit>
            <ci_upper_limit>0.100</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.060</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.082</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.222</ci_lower_limit>
            <ci_upper_limit>0.102</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Rescue Medication During Nighttime (Last Week on Treatment, Response Values)</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared.</description>
        <time_frame>Baseline and during week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Rescue Medication During Nighttime (Last Week on Treatment, Response Values)</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Weekly means obtained during the last week of each period of randomised treatment will be compared.</description>
          <population>FAS</population>
          <units>Puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.358" spread="0.092"/>
                    <measurement group_id="O2" value="-0.419" spread="0.093"/>
                    <measurement group_id="O3" value="-0.432" spread="0.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4089</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.074</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.207</ci_lower_limit>
            <ci_upper_limit>0.085</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3185</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.074</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.074</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.221</ci_lower_limit>
            <ci_upper_limit>0.072</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.013</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.074</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.160</ci_lower_limit>
            <ci_upper_limit>0.134</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Night Awakenings During the Last Week on Treatment (Score, Response Values)</title>
        <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Assessed by the patient's electronic diary (eDiary incorporated in the AM2+ device), obtained during the last week of each period of randomised treatment.</description>
        <time_frame>Baseline and during week 4</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5 Bid</title>
            <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5 qd</title>
            <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Night Awakenings During the Last Week on Treatment (Score, Response Values)</title>
          <description>MMRM results. Response was defined as change from baseline. Means are adjusted for treatment, period, patient and study baseline. Assessed by the patient's electronic diary (eDiary incorporated in the AM2+ device), obtained during the last week of each period of randomised treatment.</description>
          <population>FAS</population>
          <units>Night awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.106" spread="0.028"/>
                    <measurement group_id="O2" value="-0.104" spread="0.029"/>
                    <measurement group_id="O3" value="-0.102" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9626</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.001</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.059</ci_lower_limit>
            <ci_upper_limit>0.062</ci_upper_limit>
            <estimate_desc>Tio R2.5 bid - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9102</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM adjusted for treatment, period, patient and study baseline.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.058</ci_lower_limit>
            <ci_upper_limit>0.065</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.002</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.059</ci_lower_limit>
            <ci_upper_limit>0.063</ci_upper_limit>
            <estimate_desc>Tio R5 qd - Tio R2.5 bid</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks + 30 days if in last period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
        </group>
        <group group_id="E2">
          <title>Tio R2.5</title>
          <description>Tiotropium 2.5 mcg bid morning and evening delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
        </group>
        <group group_id="E3">
          <title>Tio R5 qd</title>
          <description>Tiotropium 5 mcg qd in the evening and matching placebo qd in the morning delivered by the Respimat inhaler, on top on maintenance therapy with iCS.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

